Data show $8.5 billion in bispecific antibody sales last year

14 March 2024
2019_pipettes_biotech_lab_research_big

New research from industry analyst Research and Markets highlights the potential of the bispecific antibody market, indicating strong growth in the present period.

Leveraging advances in medical research, this type of antibody works by using the immune system to target malignant and other diseased cells and tissues with precision.

Currently, there are over 800 candidates of this kind in clinical development, with late stage trials underway across a range of solid cancers like triple negative breast cancer, small cell lung cancer and bladder cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology